Interestingly, CD4+ T cells can drive strong anti-tumor immunity upon ICB in preclinical models of MMRd tumors with defective or low expression of MHC-I, which cannot be recognized by CD8+ T cells (180, 181). Here, CD4 is linked to neoplasm.